Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?Zacks Investment Research • 04/12/24
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/28/24
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to BuyZacks Investment Research • 03/26/24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023GlobeNewsWire • 03/21/24
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFAGlobeNewsWire • 03/13/24
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual MeetingGlobeNewsWire • 03/05/24
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate UpdateGlobeNewsWire • 11/07/23
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023GlobeNewsWire • 09/27/23
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)PRNewsWire • 09/21/23
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)Zacks Investment Research • 08/21/23
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate UpdateGlobeNewsWire • 08/11/23
APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGNBusiness Wire • 08/10/23
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/17/23
CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara SullivanGlobeNewsWire • 07/10/23